Role of Androgen Deprivation Therapy for Node-Positive Prostate Cancer

Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer.

BACKGROUND Clinically lymph node-positive (cN+) prostate cancer (PCa) is an often-fatal disease. Its optimal management remains largely undefined given a lack of prospective, randomized data to inform practice. We sought to describe modern practice patterns in the management of cN+ PCa and assess the effect of adding radiation therapy (RT) to androgen deprivation therapy (ADT) on survival using...

Impact of Adjuvant Androgen-Deprivation Therapy on Disease Progression in Patients with Node-Positive Prostate Cancer

PURPOSE The survival benefits of adjuvant androgen-deprivation therapy (ADT) in prostate cancer and lymph node metastasis remain unclear. We assessed the role of ADT in disease progression after radical prostatectomy (RP). MATERIALS AND METHODS Of 937 patients who underwent RP, we identified 40 (4.2%) who had lymph node metastasis. A total of 18 received adjuvant ADT (ADT group) and 22 were o...

Androgen Deprivation Therapy for Prostate Cancer

Androgen Deprivation Therapy for Prostate Cancer

AN D R O G E N D E P R I V A T I O N t h e r a p y ( A D T ; h e r e i n defined as medical or surgical castration) is the cornerstone treatment of advanced prostate cancer. In 1941, Huggins and Hodges first noted the beneficial effects of castration and injection of estrogens in patients with metastatic prostate cancer. The biological basis of the effect of ADT, the almost ubiquitous expressio...

Androgen deprivation therapy for prostate cancer.

CONTEXT Prostate cancer is the most common nonskin cancer and second most common cause of cancer mortality in US men. Androgen deprivation therapy (ADT), specifically surgical or medical castration, is the first line of treatment against advanced prostate cancer and is also used as an adjuvant to local treatment of high-risk disease. OBJECTIVE To review systematically the evidence on the risk...